The advisors on PolyPeptide’s credit facility expansion
Niederer Kraft Frey (NKF) advised PolyPeptide Group on the securing of additional financing under its revolving credit facility, as well as further support from its main shareholder. In connection with the deal, Homburger advised UBS, acting as the coordinator and agent of a bank consortium.
The banking syndicate in question included Danske Bank and Zürcher Kantonalbank, and agreed to increase the available capital commitments by EUR 40 million to EUR 151 million, as well as extend the term of its existing revolving credit facility to March 2028.
The context
Pursuant to the operation Draupnir Holding bolsters its presence as the Group’s main shareholder and extends the term of the existing amounts outstanding under its unsecured short-term facility with the group.
The company
Headquartered in Baar and listed on the SIX Swiss Exchange under the ticker “PPGN”, PolyPeptide is a specialised contract development & manufacturing organization for peptide- and oligonucleotide-based active pharmaceutical ingredients. The company serves its customer base in pharma and biotech, offering products and services from pre-clinical to commercial stages.
The NKF team
M&A/finance partner Philip Spoerlé (pictured above) led the NKF team on the matter, working alongside associate Selim Lötscher and junior associate Selim Tisli (both M&A/finance).
The Homburger team
Jürg Frick (pictured) led the Homburger team on the matter, working with Nathalie Scherrer (both financing and investment products) and Stefan Oesterhelt (tax).
